Aileron Therapeutics is a clinical stage chemoprotection oncology company. ALRN-6924, Co.'s MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. Co.'s clinical development program for ALRN-6924 as a selective chemoprotective agent includes: Its completed Phase 1b open-label clinical trial evaluating ALRN-6924 as a chemoprotective agent in patients with p53-mutated small cell lung cancer, undergoing treatment with second-line topotecan. The ALRN stock yearly return is shown above.
The yearly return on the ALRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|